Preliminary pharmacokinetics of PEGylated oxaliplatin polylactic acid nanoparticles in rabbits and tumor-bearing mice

Figures & data

Figure 1. Particle size distribution of concentrated OP-PLA NPs.

Figure 2. Particle size distribution of concentrated OP-PEG-PLA NPs.

Table I. OP concentrations of concentrated OP-PLA NPs.

Sample No.	1	2	3	Mean ± s
M0 (μg)	0.2921 × 10^6	0.3011 × 10^6	0.2820 × 10^6	(0.2917 ± 0.01)× 10^6
M1 (μg)	204.05	204.05	204.05	204.05
M2 (μg)	74.65	78.36	79.43	77.48 ± 2.51
P (μg/mg)	0.4430	0.4174	0.4419	0.43 ± 0.02

Table II. OP concentrations of concentrated OP-PEG-PLA NPs.

Sample No.	1	2	3	Mean ± s
M0 (μg)	0.2932 × 10^6	0.2923 × 10^6	0.2843 × 10^6	(0.2899 ± 0.01) × 10^6
M1 (μg)	230.88	230.88	230.88	230.88
M2 (μg)	75.54	77.45	78.54	77.18 ± 1.52
P (μg/mg)	0.5298	0.5249	0.5358	0.53 ± 0.01

Figure 3. Concentration–time curve of OP in rabbit plasmas.

Table III. The pharmacokinetic parameters of OP solution, OP-PLA NPs and OP-PEG-PLA NPs in rabbit plasma.

Parameter	Unit	OP sol	OP-PLA NPs	OP-PEG-PLA NPs
A	μg/ml	37.26	35.79	32.89
α	1/h	1.20	0.68	0.60
B	μg/ml	5.35	6.97	8.35
β	1/h	0.035	0.040	0.044
V (c)	L/kg	0.070	0.071	0.073
T1/2α	h	0.578	1.016	1.168
T1/2β	h	15.64	17.18	20.00
K21	1/h	0.18	0.15	0.16
K10	1/h	0.23	0.19	0.17
K12	1/h	0.82	0.39	0.31
AUC	μg/ml·h	185.48	225.22	243.93
CL(s)	mg/kg/h/(μg/ml)	0.0162	0.0133	0.0123

Figure 4. Tissue distribution of mice at 0.5 h after administration.

Figure 5. Tissue distribution of mice at 4 h after administration.

Figure 6. Tissue distribution of mice at 12 h after administration.